Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. ND BioHistory (TM)
Career
Job Search Post a Job Submit Resume Destination ND
News/Events
Local ND News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Local Support National Resources
Education
K-12 Higher Ed BioEd Reading
About
Board Advertising Feedback Home
 
News
 Local ND News
 Submit News Release
 Calendar
 Submit Event
 CEO Reading
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad: The Norway Foundation
Jobs
 
Facilities
 

ATC clean room constructors...validation guaranteed!


News

Local News

Submit News Release


Search Articles: 

  • Lilly announces completion of SGX acquisition  Eli Lilly and Company announced that it has completed the acquisition of SGX Pharmaceuticals, a San Diego-based biotechnology company focused on drug discovery and development in the area of oncology.
    Eli Lilly and Company August 20, 2008  
  • California licenses 2 companies to offer gene services  Two closely watched companies that offer consumers information about their genes have received licenses that will allow them to continue to do business in California, a state official said.
    The New York Times August 19, 2008  Andrew Pollack
  • Elanco announces acquisition of Posilac(R) dairy business  Elanco, a division of Eli Lilly and Company, announced that Lilly has signed an agreement to acquire the worldwide rights to the dairy cow supplement, Posilac(R) (sometribove), as well as the product's supporting operations, from Monsanto Company.
    Eli Lilly and Company August 20, 2008  
  • Eli Lilly and Company to acquire Monsanto's POSILAC brand dairy product  Monsanto Company announced that it has entered into an agreement to sell its POSILAC(R) bovine somatotropin brand and related business to Eli Lilly and Company. Lilly's animal health division, Elanco, is the seventh largest animal health company on a global sales basis.
    Monsanto Company August 20, 2008  
  • BMS and PDL BioPharma enter alliance to develop novel treatment for multiple myeloma  Bristol-Myers Squibb Company and PDL BioPharma announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzumab, previously known as HuLuc63, currently in Phase I development for multiple myeloma.
    Bristol-Myers Squibb Company August 19, 2008  
  • Patient side point-of-care testing enables quicker treatment decisions  Patient side point-of-care testing - where diagnostic testing is conducted at or near the site of the patient - enables doctors to make decisions on patients presenting with chest pain up to 20 minutes faster than those whose lab tests are evaluated by a standard lab.
    Abbott August 19, 2008  
  • Corn farmers who use Monsanto advanced technology eligible for lower insurance premiums  Farmers in 11 states who plant a majority of their corn acres using hybrid seeds featuring YieldGard Plus with Roundup Ready Corn 2, YieldGard VT Triple and YieldGard VT Triple PRO technology from Monsanto Company will have an opportunity to lower their crop insurance premiums in 2009.
    Monsanto Company August 19, 2008  
  • Medtronic first quarter revenue up 19 percent to $3.706 billion  Medtronic announced financial results for its first quarter of fiscal year 2009, which ended July 25, 2008. Medtronic recorded first quarter revenue of $3.706 billion, a 19 percent increase over the $3.127 billion reported in the first quarter of fiscal year 2008.
    Medtronic, Inc. August 19, 2008  
  • Pfizer says vacation with your dog before the summer ends  With canine motion sickness the leading reason pet owners are not able to take their dogs on day trips or vacation, Pfizer is encouraging more people to talk with their veterinarians about managing travel with their dog before the summer ends.
    Pfizer Inc. August 14, 2008  
  • Genentech rejects takeover bid from Roche  Roche is expected to increase its offer for the biotechnology company Genentech now that an initial $43.7 billion bid has been rejected, analysts said. Genentech said that a special committee of directors had found that Roche's offer "substantially undervalues the company."
    The New York Times August 13, 2008  Andrew Pollack

   (next 10 articles)

Search Articles: 


Submit News Release

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page

© 2008 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

NorthDakotaLifeScience.com, owned and published by Info.Resource, Inc., is a resource
for the life science industry in the state of North Dakota.